 | New Warning for Raptiva (Oct. 2005) Genentech has notified healthcare professionals about serious blood-related disorders and infections that have been associated with the drug Raptiva (efalizumab) used to treat certain patients with plaque psoriasis. The labeling for Raptiva now warns about immune-mediated hemolytic anemia, which can become apparent several months after starting treatment, and cautions prescribers to discontinue the drug if this occurs. The new labeling also includes expanded warnings about serious infections and thrombocytopenia associated with Raptiva. Additional Information: FDA MedWatch Safety Alert 2005 - Raptiva (efalizumab). http://www.fda.gov/medwatch/safety/2005/safety05.htm#Raptiva |
العربية
中国
Français
Deutsch
Ελληνική
हिन्दी
Italiano
日本語
Português
Русский
Español![Cafe Havana, Guam\](images/articles/thumbs/cafehavanathumb.jpg "Cafe Havana, Guam\")
